Mage 2mg Tablet contains Repaglinide 2mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Repaglinide belongs to the meglitinide class and functions by stimulating pancreatic beta cells to release insulin, thereby reducing postprandial blood glucose levels. It is indicated for patients with type 2 diabetes who have inadequate glycemic control with diet and exercise alone or in combination with other antidiabetic agents. Mage 2mg Tablet is typically administered shortly before meals to optimize insulin secretion in response to food intake. The dosage should be individualized based on the patient’s glycemic response and meal patterns. Common side effects may include hypoglycemia, headache, and gastrointestinal disturbances such as nausea. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of blood glucose levels is essential to minimize the risk of hypoglycemia and to adjust the dose accordingly. Mage 2mg Tablet should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular medical supervision to achieve optimal glycemic control and reduce the risk of diabetes-related complications.